Business
PRTC's Vedanta Presents Data at DDW Annual Meeting
PRTC's Vedanta Presents Data at DDW Annual Meeting.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n 24 May 2022\n \n \n \n \n PureTech Health plc\n \n \n \n \n \n \n \n \n \n PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting\n \n \n \n \n \n \n \n \n \n Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing\n \n Clostridioides\n difficile infection recurrence in subjects at high risk of recurrence\n \n \n \n \n \n \n \n \n Further CONSORTIUM study analysis shows that the VE303 high dose led to more robust colonization, which in turn correlated with prevention of recurrence\n \n \n \n \n \n \n \n \n \n Safety and colonization analyses of VE202 and VE818 Phase 1 studies show they were well tolerated, colonized robustly after vancomycin pretreatment, and were associated with increased production of secondary bile acids that are known to induce immune tolerance\n \n \n \n \n \n \n \n \n \n PureTech Health plc\n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company noted that its Founded Entity, Vedanta Biosciences, Inc. (\"Vedanta\"),\n today announced the details of three podium presentations of research informed by multiple clinical studies at Digestive Disease Week (DDW) 2022, being held both virtually and in person in San Diego, CA on May 21-24. The analyses cover several defined bacterial consortia candidates developed by Vedanta, and include assessments of safety, tolerability, efficacy, and the relationships between dosing regimen, consortium strain colonization, and restoration of a patient's resident microbial community. These analyses further deepen Vedanta's understanding of the clinical pharmacology and potential benefits of defined bacterial consortia, and help inform future clinical research. This body of data builds on\n \n published analyses\n \n from earlier clinical work that identified key factors that drive colonization of Vedanta's candidates.\n \n \n \n \n \n The full text of the announcement from\n Vedanta\n is as follows:\n \n \n \n \n \n \n \n \n Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting\n \n \n \n \n \n \n \n \n \n Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in wh...